Search - tctmd.com

Displaying 621 - 640 of 1725

Sort: Relevancy | Date

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Todd Neale

September 02, 2019

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

Caitlin E. Cox

August 06, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

Advertisement

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

TCTMD’s Top 10 Most Popular Stories for August 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

TAVR Bleeds Stand Apart From PCI-Related Events

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content